Cowen & Co. analyst Yaron Werber maintained a Hold rating on Regeneron (REGN – Research Report) today and set a price target of $349. The company’s shares closed last Monday at $304.40, close to its 52-week low of $287.66.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 10.7% and a 60.7% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Regeneron with a $374.44 average price target, a 25.6% upside from current levels. In a report issued on August 6, J.P. Morgan also maintained a Hold rating on the stock.
The company has a one-year high of $442 and a one-year low of $287.66. Currently, Regeneron has an average volume of 819K.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.